Thymosin Alpha-1 (Thymalfasin / Zadaxin) Evidence Grade: A
Thymosin Alpha-1 (Ta1) is a 28-amino-acid peptide originally isolated from thymic tissue (thymosin fraction 5) by Allan Goldstein at George Washington University in the 1970s. It is an endogenous immune modulator produced by thymic epithelial cells that plays a critical role in T-cell maturation, differentiation, and activation. The synthetic version, thymalfasin, is marketed as Zadaxin and approved in over 35 countries for treatment of chronic hepatitis B and as an immune adjuvant.
Thymosin Alpha-1 is one of the most clinically validated peptides in immunology, with extensive Phase II/III clinical trial data supporting its efficacy in viral hepatitis, vaccine enhancement, and cancer immunotherapy. It holds FDA Orphan Drug designations for hepatitis B and hepatocellular carcinoma, representing one of the most advanced peptide therapeutics in the regulatory pipeline.
Table of Contents
Overview & Introduction
Thymosin Alpha-1 (Ta1) was the first peptide isolated from thymosin fraction 5, a partially purified extract from calf thymus tissue. The thymus gland is the primary organ responsible for T-cell maturation and education in the adaptive immune system. Ta1 functions as a master immune regulator, activating dendritic cells, promoting T-cell differentiation from precursor thymocytes, enhancing T-helper and cytotoxic T-cell function, and modulating cytokine production.
The peptide's mechanism operates primarily through Toll-like receptor (TLR) signaling on dendritic cells, which are the critical antigen-presenting cells that bridge innate and adaptive immunity. By activating TLR2, TLR9, and potentially other pattern recognition receptors, Ta1 enhances the dendritic cell's ability to process and present antigens, upregulate co-stimulatory molecules, and produce immunostimulatory cytokines including IL-12, IFN-alpha, and TNF-alpha.
The clinical significance of Thymosin Alpha-1 is well established. It is approved in over 35 countries as Zadaxin (SciClone Pharmaceuticals) for chronic hepatitis B treatment and as an immune adjuvant. Clinical trials have demonstrated efficacy in improving viral clearance rates in hepatitis B, enhancing vaccine responses in immunocompromised patients, and improving outcomes when combined with cancer immunotherapy regimens. The compound has FDA Orphan Drug designations for both hepatitis B and hepatocellular carcinoma.
Unlike immunosuppressive drugs, Ta1 is an immune modulator rather than a stimulant. It enhances immune function when it is suppressed but does not cause excessive immune activation in healthy individuals. This balanced immunomodulatory profile, combined with an excellent safety record from decades of clinical use, makes it one of the most well-characterized immune peptides available.
History & Discovery
Thymosin fraction 5. Allan Goldstein and Abraham White began isolating thymic peptides at Albert Einstein College of Medicine. Thymosin fraction 5, a partially purified extract from calf thymus, was shown to restore T-cell function in thymectomized mice.
Thymosin Alpha-1 isolation. Goldstein's group purified Ta1 as the first defined peptide from thymosin fraction 5 and determined its 28-amino-acid sequence. Its immune-enhancing activity was confirmed in vitro and in vivo.
Clinical development. Synthetic thymalfasin entered clinical trials for hepatitis B, hepatitis C, and as a cancer immunotherapy adjuvant. SciClone Pharmaceuticals licensed the compound for commercial development.
International approvals. Zadaxin received regulatory approval in over 35 countries including China, Philippines, and several other Asian and South American nations. FDA Orphan Drug designations were granted.
COVID-19 and expanded research. Ta1 was investigated for COVID-19 treatment, particularly for immunocompromised patients with severe disease. Research expanded into combination immunotherapy for various cancers.
Mechanism of Action
Ta1 activates TLR2, TLR9, and potentially TLR4 on plasmacytoid and myeloid dendritic cells. This triggers MyD88/NF-kB signaling cascades that upregulate MHC class I/II molecules, co-stimulatory molecules (CD80/CD86), and immunostimulatory cytokines (IL-12, IFN-alpha, TNF-alpha). The activated dendritic cells become more effective antigen-presenting cells, bridging innate and adaptive immune responses.
Ta1 promotes the differentiation of immature thymocyte precursors into mature T-cells. It enhances CD4+ T-helper cell and CD8+ cytotoxic T-cell function, improves T-cell receptor signaling, and promotes the generation of memory T-cells. It also corrects the Th1/Th2 balance toward Th1-dominant (cell-mediated) immunity, which is critical for antiviral and anti-tumor responses.
Ta1 enhances natural killer (NK) cell cytotoxicity and macrophage phagocytic activity. These innate immune cells provide the first line of defense against viral infections and tumor cells. The dual activation of both innate (NK, macrophage) and adaptive (T-cell) immunity creates a comprehensive immune enhancement effect.
Ta1 is an immune modulator, not simply a stimulant. In immunocompromised states, it upregulates immune function. In hyperactive immune conditions, it can help restore balance. This homeostatic property is mediated partly through regulatory T-cell (Treg) modulation and cytokine balancing, making it safer than pure immunostimulants.
Research Applications
Chronic Hepatitis B
Primary approved indication. Ta1 enhances T-cell-mediated clearance of HBV-infected hepatocytes, improving HBeAg seroconversion rates when used alone or with interferon/nucleoside analogs.
Cancer Immunotherapy
Used as an adjunct to chemotherapy and radiation. Ta1 restores immune function suppressed by cancer treatment, enhances tumor antigen recognition, and improves clinical outcomes in hepatocellular carcinoma, melanoma, NSCLC, and other cancers.
Vaccine Adjuvant
Enhances vaccine-induced immune responses in immunocompromised populations (elderly, HIV, transplant patients) who respond poorly to standard vaccination.
Sepsis & Critical Care
Clinical trials in severe sepsis showed improved survival with Ta1 adjunctive therapy, attributed to immune restoration in immunoparalysis that accompanies septic shock.
Clinical Evidence
Hepatitis B Meta-Analysis
Iino et al. (2005) conducted a meta-analysis of controlled clinical trials evaluating Ta1 monotherapy and combination therapy for chronic hepatitis B. The analysis demonstrated significantly higher sustained virological response rates and HBeAg seroconversion rates with Ta1-containing regimens compared to control groups. Ta1 combined with interferon-alpha showed the highest efficacy.
PMID: 15880793
Cancer Immunotherapy Adjunct
Garaci et al. (2007) reviewed clinical evidence for Ta1 in cancer treatment, documenting improved immune parameters and clinical outcomes when Ta1 was combined with chemotherapy in hepatocellular carcinoma, melanoma, and NSCLC. The review highlighted Ta1's ability to restore immune function suppressed by chemotherapy, potentially improving both response rates and quality of life.
PMID: 17489434
TLR Mechanism Characterization
Romani et al. (2007) elucidated the molecular mechanism by which Ta1 activates dendritic cells through TLR signaling. The study demonstrated that Ta1 directly stimulates TLR2 and TLR9 on plasmacytoid dendritic cells, triggering MyD88-dependent signaling cascades that upregulate cytokine production and antigen presentation capacity.
PMID: 17184847
Sepsis Survival Improvement
Wu et al. (2013) conducted a randomized controlled trial of Ta1 as adjunctive therapy in severe sepsis. Ta1 treatment (1.6 mg SC twice daily for 7 days) significantly reduced 28-day mortality compared to standard care alone. The benefit was attributed to restoration of immune function in the immunoparalysis phase of sepsis, with increased HLA-DR expression on monocytes and restored T-cell function.
PMID: 23271722
Dosing Protocols (Research Context)
| Indication | Dose | Schedule |
|---|---|---|
| Hepatitis B (Zadaxin label) | 1.6 mg SC | Twice weekly for 6-12 months |
| Immune Support (research) | 1.6 mg SC | 2-3 times weekly |
| Vaccine Adjuvant | 1.6 mg SC | Day 0 and day 7 of vaccination |
| Sepsis (clinical trial) | 1.6 mg SC | Twice daily for 5-7 days |
The 1.6 mg dose is standard across most clinical applications. The twice-weekly maintenance schedule provides sustained immune modulation while the twice-daily sepsis protocol reflects the urgency of immune restoration in critical illness.
Administration & Reconstitution
Zadaxin (Commercial)
Supplied as lyophilized powder with sterile diluent. Reconstitute as directed. Single-use vials.
Research Grade
| Vial | BAC Water | Concentration |
|---|---|---|
| 5 mg | 2.5 mL | 2 mg/mL |
- Subcutaneous injection using insulin syringes
- Rotate injection sites (abdomen, thigh, upper arm)
- Solution should be clear and colorless
Side Effects & Safety Profile
Thymosin Alpha-1 has an exceptional safety profile established through decades of clinical use in over 35 countries and thousands of patients.
Common (Mild)
- Injection site discomfort
- Mild erythema at injection site
- Occasional fatigue
Notable Safety Features
- No immunosuppression risk
- No autoimmune exacerbation documented
- Safe in immunocompromised patients
- No drug interactions of clinical significance
- Safe with chemotherapy regimens
Stacking & Combinations
Ta1 + Interferon-Alpha
The most extensively studied clinical combination. Ta1 enhances interferon's antiviral effects while mitigating interferon-induced immune suppression. This combination shows higher HBV clearance rates than either agent alone.
Ta1 + BPC-157
For immune support during tissue repair: Ta1 provides systemic immune enhancement while BPC-157 drives local tissue repair. Relevant for post-surgical recovery research.
Ta1 + Epithalon
For immune rejuvenation: Ta1 directly activates T-cell immunity while Epithalon restores thymic/pineal function through melatonin and telomerase pathways. Addresses immune aging from both effector and regulatory perspectives.
Storage & Stability
| Form | Conditions | Duration |
|---|---|---|
| Lyophilized | Refrigerated (2-8°C) | 36+ months |
| Reconstituted | Refrigerated | Use within 24 hours (Zadaxin) / 21 days (BAC water) |
Regulatory Status
- International: Approved in 35+ countries as Zadaxin for hepatitis B and immune modulation (China, Philippines, many others).
- United States: Not FDA-approved. FDA Orphan Drug designation for hepatitis B and hepatocellular carcinoma. Available as research peptide and through compounding.
- WADA: Not on the Prohibited List.
Frequently Asked Questions
Is Thymosin Alpha-1 approved for medical use?
How does it differ from TB-500 (Thymosin Beta-4)?
Can it be used alongside vaccines?
References
- Iino S. "Thymosin alpha 1 therapy for chronic hepatitis B." Hepatol Res. 2005;33(2):97-102. PMID: 15880793
- Garaci E. "Thymosin alpha 1 in cancer treatment." Ann N Y Acad Sci. 2007;1112:187-196. PMID: 17489434
- Romani L, et al. "Thymosin alpha 1 activates dendritic cells through TLR signaling." Blood. 2007;109(7):2797-2805. PMID: 17184847
- Wu J, et al. "Thymosin alpha 1 for severe sepsis." Crit Care. 2013;17(1):R8. PMID: 23271722
Related Pages
Concise compound overview
Step-by-step protocol
Thymosin Beta-4 comparison
Immune rejuvenation partner
Medical Disclaimer: This article is for educational and research reference purposes only. While Thymosin Alpha-1 is approved in some countries, this does not constitute prescribing guidance. Consult a qualified healthcare professional. See our full Medical Disclaimer.
© 2026 Path to Peptides™. For research and educational purposes only. Not medical advice.
Some links on this site may earn a commission at no cost to you.